zintick
REPL Replimune Group+23.1%Stock moveEarnings and guidance

Replimune Stock Jumps 23% on Day It Reported Fiscal Second Quarter and TUDRIQEV Launch Update

The company said TUDRIQEV reached patients on Oct. 6 and that more than 15 institutions have prescribed it, though the release does not state a direct cause for the rally.

By Zintick Team · Editor: Kratik Mehta
Published

Scientists use the idea and hold the beaker with green chemicals in the laboratory.
Photo: Oakland Images/Shutterstock.com

Key points

  • Replimune (REPL) rose 23.1% on Oct. 28, 2026, closing at $16.06 from $13.05, the day it reported fiscal Q2 results
  • TUDRIQEV first delivered to patients Oct. 6; more than 15 institutions have prescribed it
  • Cash and equivalents were $307.8 million at Sept. 30, 2026
  • Q2 net loss was $57.1 million, narrower than $83.1 million a year earlier

Replimune Group, Inc. (Nasdaq: REPL) rose 23.1% on Wednesday, Oct. 28, 2026, closing at $16.06 from a previous close of $13.05, while the S&P 500 ETF (SPY) gained 0.34%. Volume ran at about four times its usual level. The company released its fiscal second-quarter results the same morning, in a 8-K filed at 7:05 a.m. ET that attached the news release.

Commercial launch update

The release said TUDRIQEV, the company's treatment for advanced melanoma, was first delivered to patients on Oct. 6. Replimune said more than 15 institutions have prescribed it and that it has actively engaged more than 70 percent of its initial 200 priority accounts. The company also cited NCCN inclusion as a category 2A recommendation and said multiple payer policies covering the label have been published.

Cash and losses

Cash and cash equivalents were $307.8 million as of Sept. 30, 2026, up from $268.9 million in cash and short-term investments at fiscal year-end March 31, 2026. The increase reflected about $141.0 million in net proceeds from an August 2026 equity offering and a $15.0 million debt draw in September. The company said that cash should fund operations for more than twelve months.

Net loss for the quarter was $57.1 million, narrower than the $83.1 million loss a year earlier. R&D expenses fell to $34.4 million from $57.9 million.

No stated trigger for the move

The release and the 10-Q do not single out a specific event as the reason for the share-price gain, and no analyst actions were tied to the session.

Sources

Written with AI from SEC filings and market data, and checked against those sources before publishing. Our editorial standards.

REPL page →

Filings, figures and price history are on the Replimune Group page.